Oramed Pharmaceuticals Inc. — FY2016 Form 10-K
Reporting period: Fiscal year ended August 31, 2016. Although the request identifies 2016 Q4, this is an annual report; standalone fourth-quarter financial results are not clearly provided. Amounts below are U.S. dollars.
Business context and reporting period
Oramed is a development-stage pharmaceutical company focused on oral delivery of insulin (ORMD-0801) and other peptides, including oral exenatide (ORMD-0901). It has no product sales and depends on financing and licensing arrangements to fund research and development.
In April 2016, Oramed completed a U.S. Phase IIb trial of ORMD-0801 in 180 patients with type 2 diabetes. The company reported that the trial met its primary, secondary and exploratory endpoints, with statistically significant glucose reductions on several measures and acceptable tolerability. A dose-finding Phase IIa trial began in October 2016. An exclusive China, Hong Kong and Macau license to HTIT covers ORMD-0801.
Key financial metrics
| Metric | FY2016 | FY2015 |
|---|---|---|
| License-related revenue | $641,000 | None |
| Cost of revenue | $490,000 | None |
| Research and development, net | $7.709 million | $4.781 million |
| General and administrative expense | $2.452 million | $2.602 million |
| Operating loss | $10.010 million | $7.383 million |
| Net loss | $10.964 million | $7.232 million |
| Loss per share, basic and diluted | $0.87 | $0.67 |
| Net cash provided by (used in) operating activities | $4.655 million | $(4.946) million |
| Cash and cash equivalents at year-end | $3.907 million | $3.213 million |
| Working capital | $27.609 million | $15.883 million |
| Total assets | $42.830 million | $26.354 million |
| Stockholders’ equity | $26.190 million | $24.828 million |
Revenue was licensing-related, not product revenue. The filing recognizes license consideration over time through an expected product-submission date of June 2023; accordingly, reported revenue does not represent cash received in the year. Cost of revenue includes related royalty obligations. A conventional operating margin is not meaningful given the company’s development-stage status and very limited revenue.
At August 31, 2016, cash, short- and long-term deposits, restricted cash and marketable securities totaled approximately $42.1 million. The company reported no conventional borrowings; liabilities were mainly deferred revenue and operating accruals. Current liabilities were $3.621 million and long-term liabilities were $13.019 million, including $12.604 million of deferred revenue.
Material changes versus the prior year
- R&D expense rose 61%, primarily reflecting clinical-trial costs, including the ORMD-0801 Phase IIb trial.
- Net loss increased by $3.732 million, while loss per share increased from $0.67 to $0.87.
- Revenue of $641,000 was recorded for the first time; no revenue was recorded in FY2015.
- Working capital increased by $11.726 million, primarily following HTIT’s $12 million equity investment. Financing activities provided $12.043 million in FY2016.
- Operating cash flow turned positive, principally because of increased deferred revenue from the license arrangement; investing activities used $16.010 million, largely for deposits and securities.
- A $1.350 million withholding tax on HTIT milestone receipts contributed to FY2016 income-tax expense of $1.335 million despite the pretax loss.
Outlook, commentary, risks and unusual items
- Management estimated approximately $16 million would be needed to finance activities in the 12 months following August 31, 2016, and said available resources were expected to support planned activity for at least 12 months. Additional financing may still be needed; there is no assurance it will be available on acceptable terms.
- Oramed expected R&D to remain its largest operating expense. Future development depends on clinical outcomes, regulatory approvals, third-party manufacturing and suppliers, and potential commercial partners.
- The HTIT license provides for up to approximately $37.5 million in payments, subject to conditions and milestones, plus royalties generally stated at 10% of net sales, potentially reduced under specified circumstances. The company reported receiving $3 million in January 2016, $6.5 million and $4 million in July 2016, and a further $4 million in October 2016. Some payments remain conditional.
- Key risks include failure or delay in clinical trials or regulatory approval, continued losses, need for further capital and possible shareholder dilution, reliance on HTIT and suppliers, competition, intellectual-property challenges, and political, currency and operating risks in Israel. The company does not hedge its foreign-currency exposure.
- Unusual financial items include deferred recognition of substantial license consideration and the $1.350 million withholding-tax expense. The filing states there were no material legal proceedings and no material off-balance-sheet arrangements. The auditor issued an unqualified opinion; management reported effective disclosure controls and internal control over financial reporting.
Important facts for investors to verify
- Review the full Phase IIb data and subsequent trial results; the 10-K’s positive topline statements do not establish regulatory approval or commercial efficacy.
- Confirm the status, timing and conditions of remaining HTIT milestone payments, regulatory work in the licensed territory, and any potential royalty reductions.
- Assess whether the reported cash, deposits and securities are available as expected, and compare the stated $16 million funding need with actual spending and subsequent financing.
- Examine the license-revenue recognition schedule and the withholding-tax treatment, including whether any tax credit or recovery becomes realizable.
- Evaluate dilution from future equity financing and outstanding options, warrants and restricted stock units, as well as market and liquidity risks in the D.N.A investment.